Progress in the development of fatty acid synthase inhibitors as anticancer targets
Authors:
- 1 October 2015
- journal article
- review article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (20) , 4363-4369
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Different fatty acid metabolism effects of (−)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma lung cancerBMC Cancer, 2012
- Charting, Navigating, and Populating Natural Product Chemical Space for Drug DiscoveryJournal of Medicinal Chemistry, 2012
- Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75Metabolomics, 2011
- Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthaseBreast Cancer Research and Treatment, 2010
- Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-mycBMC Cancer, 2010
- Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathwaysBMC Cancer, 2010
- Fatty Acid Synthase As a Potential Therapeutic Target in CancerFuture Oncology, 2010
- Cancer prevention by tea: animal studies, molecular mechanisms and human relevanceNature Reviews Cancer, 2009
- Natural products in drug discoveryDrug Discovery Today, 2008
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006